ReviewDiscover oncology2025
Precision medicine research progress based on colorectal cancer organoids.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Review
- Anti-Metastatic Effects ofInternational journal of molecular sciences · 2025Article
- Sophisticated Interfaces Between Biosensors and Organoids: Advancing Towards Intelligent Multimodal Monitoring Physiological Parameters.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Organoids are cultures that use stem cells to induce differentiation or clinical samples as raw materials to form three-dimensional spatial structures through specific culture systems, thereby simulating the structure and function of tissues in vivo. Organoids are characterized by their ease of construction, long-term stable passage, clinical authenticity, and application in high-throughput drug screening. Patient-derived organoids have great application value in colorectal cancer research and individualized treatment. In this review, recent advances in colorectal cancer organoid culture technology, clinical individualized drug sensitivity assessment, new drug screening, drug mechanism research, nanomedicine-based applications, and imaging technology are summarized. These advancements will provide support for the precise diagnosis and treatment of colorectal cancer and the development of new treatment strategies, which will have significant scientific value and clinical transformation value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.